Retatrutide is an investigational weight loss injection that works by simultaneously activating three hormone receptors — GLP-1, GIP, and glucagon — making it the first triple receptor agonist of its kind in clinical development. This unique triple-action mechanism sets it apart from approved medicines such as semaglutide and tirzepatide, and has generated significant scientific interest following promising Phase 2 trial results. This article explains how retatrutide works, the conditions it is being studied for, its potential side effects, and what UK patients need to know about its current regulatory status and availability.

What Is Retatrutide and Its Current Status in the UK

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly. It has not received MHRA or EMA marketing authorisation and is not available in the UK as of 2025.

Retatrutide is an investigational injectable medication being developed by Eli Lilly and Company. It belongs to a novel class of drugs known as triple receptor agonists, meaning it simultaneously activates three distinct hormone receptors involved in appetite regulation and metabolic function:

• GLP-1 (glucagon-like peptide-1) receptor

• GIP (glucose-dependent insulinotropic polypeptide) receptor

• Glucagon receptor

This triple-action mechanism distinguishes retatrutide from currently approved medicines such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP receptor agonist).

Understanding how retatrutide works requires a brief look at the hormones it targets. GLP-1 is an incretin hormone released from the gut after eating; it stimulates glucose-dependent insulin secretion, reduces appetite, and slows gastric emptying. GIP also augments glucose-dependent insulin secretion, though its effects on appetite and gastric emptying are more context-dependent and may be influenced by co-agonism with GLP-1. Glucagon, produced by the pancreatic alpha cells, typically raises blood glucose and promotes fat breakdown. Retatrutide's glucagon receptor activity is hypothesised to enhance energy expenditure and fat oxidation, potentially offering metabolic benefits beyond those seen with existing therapies — though this remains an area of active investigation rather than established fact.

In Phase 2 trials, retatrutide was administered as a once-weekly subcutaneous injection with a structured dose-escalation protocol. Phase 3 trials are reported to be ongoing; readers wishing to verify current trial status and recruitment are encouraged to consult ClinicalTrials.gov or the EU Clinical Trials Information System (EU CTIS).

As of 2025, retatrutide has not been granted marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). It is therefore not available through the NHS or licensed private prescribers in the UK. Readers can confirm the absence of a UK marketing authorisation via the MHRA's products search and the EMA's EPAR portal.

Conditions Retatrutide Is Being Investigated For

Retatrutide is primarily being investigated for obesity and overweight, with additional studies exploring type 2 diabetes, MASH, and cardiovascular risk reduction. It is not currently approved or indicated for any condition in the UK.

The primary focus of retatrutide's clinical development is obesity and overweight, particularly in adults with weight-related health complications. A Phase 2 trial published in The New England Journal of Medicine (Jastreboff et al., 2023) reported a mean body weight reduction of approximately 24% at the highest dose over 48 weeks in participants without type 2 diabetes — results that attracted considerable scientific interest. It is important to note that this figure represents the mean outcome at the highest dose in a carefully selected trial population; results in broader, real-world populations may differ.

Beyond obesity, retatrutide is being investigated for several related metabolic conditions, including:

• Type 2 diabetes mellitus — given its potential to improve insulin secretion and reduce blood glucose levels through GLP-1 and GIP receptor activation; evidence to date comes from early-phase studies, with further trials ongoing

• Metabolic dysfunction-associated steatohepatitis (MASH) — previously referred to as non-alcoholic steatohepatitis (NASH), this is a progressive liver condition closely linked to obesity and insulin resistance; the glucagon receptor component is hypothesised to help reduce hepatic fat accumulation, though clinical evidence in this area is still emerging

• Cardiovascular risk — weight loss and improved glycaemic control are established contributors to lower cardiovascular risk, but no completed cardiovascular outcomes trial for retatrutide exists; any cardiovascular benefit therefore remains unproven at this stage

MASH sits within the broader spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD), the current internationally agreed terminology replacing NAFLD/NASH. The British Liver Trust provides accessible patient-facing information on these conditions.

It is important to note that retatrutide is not currently indicated or approved for any of these conditions in the UK. Patients interested in weight management or metabolic health should speak with their GP about currently approved and NICE-recommended treatment options.

Potential Side Effects and Safety Considerations

The most commonly reported side effects are gastrointestinal, including nausea, vomiting, diarrhoea, and constipation, typically mild to moderate and most prominent during dose escalation. Additional safety areas under monitoring include heart rate changes, muscle mass preservation, and thyroid C-cell effects.

As with other medicines in the incretin-based therapy class, retatrutide's clinical trials have identified a range of side effects, most of which relate to its gastrointestinal activity. Because the drug acts on gut hormone receptors and slows gastric emptying, the most commonly reported adverse effects in Phase 2 trials include:

• Nausea (particularly during dose escalation)

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

These effects were generally described as mild to moderate in severity and tended to diminish over time. The structured dose-escalation protocol used in trials was designed to minimise gastrointestinal discomfort.

The addition of glucagon receptor agonism introduces some safety considerations not seen with GLP-1 or dual GLP-1/GIP agonists alone. Phase 2 data noted increases in heart rate with retatrutide, consistent with observations across the incretin class. Blood pressure, however, often decreases with significant weight loss, and early data do not clearly indicate a net increase in blood pressure; this area continues to be evaluated in ongoing trials.

Other safety areas under investigation include:

• Lean muscle mass preservation — significant weight loss can result in loss of muscle tissue, and researchers are monitoring body composition changes

• Bone density — a consideration with rapid weight loss in general

• Thyroid C-cell effects — a class concern for GLP-1 receptor agonists, though clinical significance in humans remains uncertain

• Pancreatitis and gallbladder disease — signals observed across the incretin class are being monitored for retatrutide, though no established causal link has been confirmed for this agent specifically

• Dehydration and kidney function — prolonged vomiting or diarrhoea can lead to dehydration and, in some cases, acute kidney injury; maintaining adequate fluid intake is important

When to seek urgent help: Anyone taking a medicine in this class who experiences severe or persistent abdominal pain, inability to keep fluids down, signs of an allergic reaction (such as swelling of the face, lips, or throat, or difficulty breathing), or any other rapidly worsening symptoms should seek urgent medical attention — call NHS 111 or 999 in an emergency.

Because retatrutide is not yet approved, its full safety profile in diverse, real-world populations is not yet established. Patients should not attempt to obtain retatrutide outside of regulated clinical trial settings, as unlicensed medicines carry significant and unpredictable risks.

Suspected side effects from any medicine can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

What UK Patients Should Know About Access and Availability

Retatrutide is not available in the UK through any licensed or NHS-approved route, and purchasing it outside a regulated clinical trial is legally uncertain and potentially dangerous. UK patients can explore approved alternatives such as semaglutide (Wegovy®) or tirzepatide (Mounjaro®) via their GP or specialist obesity service.

For UK patients curious about retatrutide, the most important point is straightforward: retatrutide is not currently available in the UK through any licensed or NHS-approved route. It has not received marketing authorisation from the MHRA, and NICE has not issued any guidance on its use. Purchasing or using retatrutide outside of a regulated clinical trial would be both legally uncertain and potentially dangerous.

Patients who are interested in participating in clinical research may wish to explore whether they are eligible for ongoing trials. The NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk), ClinicalTrials.gov, and the EU Clinical Trials Information System (EU CTIS) list studies recruiting participants in the UK and Europe. Eligibility criteria are strict, and participation involves careful medical supervision — this is not a route to accessing a weight loss medicine informally.

For those seeking help with obesity or type 2 diabetes management right now, there are several MHRA-approved options available through the NHS and licensed private providers, including:

• Semaglutide 2.4 mg (Wegovy®) — approved by the MHRA for chronic weight management; NICE technology appraisal guidance (TA875) supports its use in specialist weight management services in England, subject to eligibility criteria and local availability

• Tirzepatide (Mounjaro®) — approved by the MHRA for type 2 diabetes and, more recently, for weight management; NICE technology appraisal guidance (TA1026) covers its use for weight management in England, again subject to eligibility criteria, specialist service referral, and local commissioning and supply

• Orlistat — an older, orally administered option available on NHS prescription in primary care

Access to GLP-1 and dual agonist therapies for weight management is currently via specialist services and remains subject to NICE criteria, local commissioning decisions, and ongoing supply considerations. Patients should speak with their GP or a specialist obesity service to discuss which treatments are appropriate for their individual circumstances. The current NICE obesity guideline and associated pathways provide the framework for NHS treatment decisions in England.

Finally, patients should be cautious about online sources claiming to sell retatrutide or other weight loss injections. The MHRA has issued repeated warnings about counterfeit and unlicensed weight loss injections circulating online. Purchasing such products carries serious health risks and offers no guarantee of safety, quality, or efficacy. Always obtain medicines through regulated UK pharmacies and licensed prescribers.

Frequently Asked Questions